BioLife Solutions (NASDAQ:BLFS) CFO Sells $12,195.12 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 588 shares of the stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $20.74, for a total transaction of $12,195.12. Following the transaction, the chief financial officer directly owned 220,649 shares in the company, valued at approximately $4,576,260.26. The trade was a 0.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, January 6th, Troy Wichterman sold 990 shares of BioLife Solutions stock. The stock was sold at an average price of $25.59, for a total transaction of $25,334.10.
• On Tuesday, December 9th, Troy Wichterman sold 1,033 shares of BioLife Solutions stock. The stock was sold at an average price of $25.13, for a total transaction of $25,959.29.

BioLife Solutions Trading Down 1.3%

Shares of BioLife Solutions stock opened at $19.86 on Friday. BioLife Solutions, Inc. has a twelve month low of $19.10 and a twelve month high of $29.62. The firm has a market capitalization of $959.24 million, a PE ratio of -180.53 and a beta of 1.90. The firm’s 50-day moving average price is $23.37 and its 200 day moving average price is $25.07.

Analyst Upgrades and Downgrades

BLFS has been the subject of several research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, January 21st. HC Wainwright restated a “buy” rating and issued a $32.00 price objective on shares of BioLife Solutions in a report on Monday, December 29th. Zacks Research raised shares of BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 23rd. Northland Securities set a $34.00 target price on shares of BioLife Solutions in a report on Monday, January 5th. Finally, UBS Group reiterated a “buy” rating on shares of BioLife Solutions in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Hedge Funds Weigh In On BioLife Solutions

Institutional investors and hedge funds have recently bought and sold shares of the company. Jacobs Levy Equity Management Inc. purchased a new stake in shares of BioLife Solutions in the 1st quarter valued at approximately $283,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of BioLife Solutions by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,422 shares of the medical equipment provider’s stock worth $489,000 after buying an additional 914 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of BioLife Solutions during the 1st quarter valued at approximately $1,091,000. Strs Ohio purchased a new stake in shares of BioLife Solutions during the 1st quarter valued at approximately $153,000. Finally, Vestmark Advisory Solutions Inc. lifted its holdings in BioLife Solutions by 160.3% in the second quarter. Vestmark Advisory Solutions Inc. now owns 24,438 shares of the medical equipment provider’s stock valued at $526,000 after acquiring an additional 15,049 shares during the last quarter. 93.24% of the stock is currently owned by institutional investors and hedge funds.

BioLife Solutions News Summary

Here are the key news stories impacting BioLife Solutions this week:

• Positive Sentiment: Analyst/preview: Seeking Alpha highlights BioLife’s strategic refocus on core biopreservation media and vials, forecasting ~17–20% revenue growth in FY2026, positive GAAP net income and mid‑60s gross margins; cites the PanTHERA acquisition and a QKine partnership as drivers of higher ARPU and next‑gen product launches by late‑2026. BioLife Looks Strong For Fiscal Year 2026
• Positive Sentiment: Company presentation/press release: BioLife reiterated its growth and strategic refocus in a recent presentation, reinforcing management’s turnaround narrative and the FY26 outlook that underpins the Seeking Alpha preview. BioLife Solutions Highlights Growth and Strategic Refocus in Presentation
• Neutral Sentiment: Short‑interest data published for early March shows zero shares / 0.0 days‑to‑cover — this appears erroneous or non‑informative and does not indicate material short pressure at present. MarketBeat BLFS
• Negative Sentiment: Insider selling: Multiple senior executives (CFO, CMO, EVP, CTO and others) disclosed modest open‑market sales (hundreds of shares apiece at ≈$20.74). Amounts are small relative to their holdings, but clustered sales can trigger short‑term headline risk and investor caution. Insider trading alert

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.